Marksans Pharma Share Price Target 2025, Q4 Results and More

Marksans Pharma

Marksan Pharma was started in 1992 with Mumbai as its headquarters. The company engages in R&D and marketing of generic pharmaceuticals that are approved by leading regulatory agencies like USFDA, UK MHRA, and Australian TGA.

The company has been producing over-the-counter (OTC) and prescription drugs for antidiabetics, pain management, Gastroenterological, and Anti-allergies. The company has 300+ products and serves 50+ markets around the world.

Marksans Pharma Share Price Target 2025 

The share price target for Marksans Pharma in 2025 is 253.54 INR, which is fixed by third-party stock analysts. so these might fluctuate from analyst to analyst. The price is fixed based on factors like future supply and demand, technical levels, and company fundamentals.

However, the most common fundamental one can rely on is the P/E ratio. Which is a price-to-earning ratio. The share price target of any stock trading company is also assessed by qualified institutional investors like mutual fund groups and stock brokerage companies or by the company's board of directors to see if their shares achieve the set target.

This last scenario is least expected to occur, as the company fixing the price is like shooting in the leg. So in our case, the price target is for more seasoned investors who know the financial fundamentals well. 

Marksans Pharma Q4 Results 

Marksan Pharma released its Q4 results on May 30th, after the board of directors meeting that took place from 10.30 to 11.30 pm. The company posted overall good results in operating revenue with 15.2% growth and EBITDA with 0.1% growth.

On the PAT (Profit After Tax) and EPS Earnings Per Share, the company had a negative growth compared with previous quarters of the same year, with the PAT having a 6.1% decrease and the EPS a 12.1% decrease.

On business sales abroad, the company posted a balanced report with US and North American markets, with UK and European markets posting a positive report of growth with 26.6% and 12.9%, respectively. and in the rest of the world (ROW), the company had seen its growth shrink by 17.1%.

Commenting on the results, the company's managing director, Mark Saldanha, said the company had done exceptionally well in revenue and profitability for FY24 overall. The company has exceeded the revenue target of 2000 crores of rupees, and it is confident in its sustained long-term value for shareholders.

In the same board meeting, the company decided on the final dividend of.6% equity share with a face value of Rs 1.

Marksans Pharma Share price 

The Marksans Pharma share price was 149 Rs on May 31st when trading started today the company price has been in the red after the Q4 results were posted. At the end of the day prices hover at 148 Rs. 

Marksans Pharma News

Marksans Pharma has been in the news for the past two days after the company posted the Q4 results for FY 23–24. It caused a complete blood bath for the company’s share in the stock market, with the price reaching a new low of 145 Rs on May 30th, when stock trading ended for that day.

The reasons stated are low EBITDA with 0.1% growth for current Q4 by some analysts. And the overall price percentage fell by 12.93%.